313 results on '"Orillion A"'
Search Results
2. 609 Pregnancy outcomes in systemic lupus erythematosus (SLE): data from a multiethnic, multinational Latin American cohort
3. POS0741 IMPACT OF ACTIVE LUPUS NEPHRITIS ON THE QUALITY OF LIFE OF PATIENTS FROM A LATIN AMERICAN LUPUS COHORT
4. POS0114 LUPUS NEPHRITIS AND RESPONSE TO TREATMENT IN LATIN AMERICA
5. POS1016 THE IMPACT OF ACTIVE LUPUS NEPHRITIS ON WORK PRODUCTIVITY IN PATIENTS FROM A LATIN AMERICAN LUPUS COHORT
6. First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial
7. LSO-086 Pregnancy outcomes in systemic lupus erythematosus: data from a multiethnic, multinational Latin American cohort
8. LP-149 Latin-American systemic lupus erythematosus clusters
9. LP-139 Baseline characteristics of a longitudinal, multinational, multiethnic study of lupus patients, with or without lupus nephritis
10. New Directions for Student Outreach: The University of California's School - University Partnerships
11. POS1519 BASELINE CHARACTERISTICS OF A LONGITUDINAL, MULTINATIONAL, MULTIETHNIC STUDY OF LUPUS PATIENTS, WITH OR WITHOUT LUPUS NEPHRITIS
12. AB0578 LATIN-AMERICAN SYSTEMIC LUPUS ERYTHEMATOSUS CLUSTERS
13. AB0580 PREGNANCY OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): DATA FROM A MULTIETHNIC, MULTINATIONAL LATIN AMERICAN COHORT
14. POS0169 PREDICTORS OF FIRST HOSPITALIZATIONS DUE TO DISEASE ACTIVITY AND INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
15. Supplementary Figure 5 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
16. Data from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
17. Supplementary Figure Legends from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
18. Supplementary Figure 4 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
19. Supplementary Figure 3 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
20. Supplementary Figure S5 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
21. Data from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
22. Supplementary Fig 3 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
23. Supplementary Fig. 1 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
24. Supplementary Figure 2 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
25. Supplementary Figure 1 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
26. Supplementary Figure 6 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
27. Supplementary Fig. 7 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
28. Supplementary Fig. 5 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
29. Supplementary Fig. 6 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
30. Supplementary Figure legend from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
31. Supplementary Fig. 2 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
32. Supplementary Fig 4 from Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
33. Data from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
34. Data from EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
35. Data from Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma
36. Supplementary Table S1 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
37. Supplementary Fig. 5 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
38. Supplementary Fig. 2 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
39. Supplementary Fig. 4 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
40. Supplementary Figure Legend from Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma
41. Data from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
42. Supplementary Fig. 6 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
43. Supplementary Fig. 8 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
44. Table S1 from Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
45. Supplementary Figure 7 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
46. Supplementary Figure Legend from EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
47. Supplemental Figures from EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
48. Supplementary Table 2 from EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
49. Supplementary Fig. 3 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
50. Supplementary Fig. 1 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.